skip to Main Content
Get Board Certified
BECOME CERTIFIED
Overview
Board Eligibility
Fees
FAQs
Candidate Handbook
ABOUT THE EXAM
BCMTMS™ Exam Overview
Examination Scheduling
Testing Dates
Exam Content Outline
Exam Prep Resources
Handbook
test
APPLY NOW
Maintain Certification
MAINTAIN CERTIFICATION
Renewal Cycle
Recertification Process
Recertification Handbook
MTM Certificate
Menu 3
About
ABOUT NBMTM
Mission, Vision & Values
History
Leadership & Governance
Accreditation
Volunteer Opportunities
ABOUT OUR CERTIFICATION
MTM Certification
BCMTMS
A Trusted Credential
Reports and Pass Rates
my
NBMTM
Search
Search
Submit
Menu
Feed Items
Home
|
Carfilzomib treatment for multiple myeloma tied to higher CV risk
Carfilzomib treatment for multiple myeloma tied to higher CV risk
January 5, 2018
Carfilzomib treatment for multiple myeloma tied to higher CV risk
Published on 01/04/2018
Tweet
Share
Share
previous post:
Fewer cardiovascular events when statin guidelines apply more broadly
next post:
Systemic therapy of aggressive fibromatosis in children and adolescents: Report of the Cooperative Weichteilsarkom Studiengruppe (CWS)
Get Board Certified
Overview
Board Eligibility
BCMTMS™ Exam Overview
Testing Dates
Fees
Exam Content Outline
Exam Prep Resources
Candidate Handbook
Maintain Certification
Renew Certification
Renewal Cycle
Recertification Process
Recertification Handbook
About
Mission, Vision & Values
History
Leadership & Governance
Accreditation
MTM Certification
A Trusted Credential
Login
Back To Top
